Eli Lilly and Company Stock News

The market for weight management medicines has been the hottest therapeutic area in the past two years. Plenty of companies are now trying to make waves in this space.

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity and diabetes rates collide with expanding middle-class incomes, the country is becoming a pivotal battleground for the two drugmakers.

Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk's recently launched Wegovy.

Die Aktie von Novo Nordisk scheint sich inzwischen stabilisiert zu haben, sodass nicht nur Schnäppchenjäger übe reinen Einstieg nachdenken könnten.

Eli Lilly is positioned for a 30-50% return in the next 12 months based on a nexus of value and growth. While others hesitate on greatness, I buy at the prices everyone else wishes they did. Risks are the price of admission to elite returns. No champion in the market rises without scar tissue.

Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

Eli Lilly (LLY 1.12%) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might think it's too late to invest.